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We describe formulation and evaluation of novel dissolving polymeric microneedle (MN) arrays for the
facilitated delivery of low molecular weight, high dose drugs. Ibuprofen sodium was used as the model
here and was successfully formulated at approximately 50% w/w in the dry state using the copolymer
poly(methylvinylether/maleic acid). These MNs were robust and effectively penetrated skin in vitro,
dissolving rapidly to deliver the incorporated drug. The delivery of 1.5 mg ibuprofen sodium, the theoretical
mass of ibuprofen sodium contained within the dry MN alone, was vastly exceeded, indicating extensive
delivery of the drug loaded into the baseplates. Indeed in in vitro transdermal delivery studies, approximately
33 mg (90%) of the drug initially loaded into the arrays was delivered over 24 h. Iontophoresis produced
no meaningful increase in delivery. Biocompatibility studies and in vivo rat skin tolerance experiments raised
no concerns. The blood plasma ibuprofen sodium concentrations achieved in rats (263 μg ml−1 at the 24 h
time point) were approximately 20 times greater than the human therapeutic plasma level. By simplistic
extrapolation of average weights from rats to humans, a MN patch design of no greater than 10 cm2 could
cautiously be estimated to deliver therapeutically-relevant concentrations of ibuprofen sodium in humans.
This work, therefore, represents a signiﬁcant progression in exploitation of MN for successful transdermal
delivery of a much wider range of drugs.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Microneedle (MN) arrays are micron scale, minimally-invasive
devices that painlessly by-pass the skin's stratum corneum (SC), which
is the principal barrier to topically-applied drugs. MN arrays have
been extensively investigated in recent years as a means to enhance
transdermal drug and vaccine delivery. The current trend in MN-based
research has involved recognition of the dubious biocompatibility of
silicon and the potential for inappropriate reuse of silicon or metal
microneedles, which remain fully intact after removal from a patient's
skin. Consequently, much recent effort has focussed on MN arrays pre-
pared from drug-loaded gels of FDA-approved biocompatible polymers.
Such systems typically dissolve in skin interstitial ﬂuid to release their
drug payload.
Dissolving MN arrays have been shown to enhance transdermal
and intradermal delivery of numerous substances, including insulin
[1,2], 5-aminolevulinic acid [3], sulforhodamine B [4], low molecular
weight heparin [5], ovalbumin [6,7], adenovirus vector [7] and a variety
of vaccine antigens [8,9]. Synergistic effects of dissolving MN arrays
used in combination with other enhancing strategies have been report-
ed recently by Garland et al. [10], where the use of drug-loaded dissolv-
ing poly(methyl-vinyl-ether-co-maleic-acid) MN arrays was coupled
with iontophoresis.
A schematic depiction of the means by which dissolving MN arrays
deliver their payload is presented in Fig. 1(A). The compounds delivered
to date by dissolvingMNs have typically been of high potency, meaning
only a low dose is required to achieve a therapeutic affect (e.g. insulin)
[11] or elicit the required immune response [8,9]. Accordingly, dissolv-
ing MN arrays have proven to be an extremely successful delivery
strategy, even though high molecular weight biomolecules are only
normally delivered from the dissolving MNs themselves and not the
baseplate upon which they are formed [11]. Clearly, the majority of
marketed drug substances are not low dose high potency biomolecules.
Indeed, many drugs require oral doses of several hundred milligrams
Journal of Controlled Release 180 (2014) 71–80
⁎ Corresponding author at: School of Pharmacy, Queen's University Belfast, Medical
Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK. Tel.: +44 28 90 972 251;
fax: +44 28 90 247 794.
E-mail address: r.donnelly@qub.ac.uk (R.F. Donnelly).
http://dx.doi.org/10.1016/j.jconrel.2014.02.007
0168-3659/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / j conre l
per day in order to achieve therapeutic plasma concentrations in
humans. Until now, such high doses could not be delivered transder-
mally from a patch of reasonable size, even for molecules whose
physicochemical properties are ideal for passive diffusion across
the skin's stratum corneum barrier. Therefore, transdermal delivery
has traditionally been limited to fairly lipophilic low molecular
weight, high potency drug substances. Since most drug substances
do not possess these properties, the transdermal delivery market
has not expanded beyond around 20 drugs [12–14]. In the present
study, we aimed to overcome the current limitations of both conven-
tional transdermal delivery and dissolving MN strategies to deliver,
for the ﬁrst time, therapeutically-relevant doses of a model low
molecular weight, high dose drug molecule.
2. Materials and methods
2.1. Chemicals
Polyethylene glycol (PEG, MW 10,000 Da), ibuprofen sodium,
poly(vinyl alcohol) (PVA, MW 31,000–50,000 g/mol), polyvinylpyr-
rolidone (PVP, MW 40,000 g/mol), alginic acid sodium salt and the
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) cell viability reagent were purchased from Sigma Aldrich,
Dorset, UK. Eudragit® S (MW 125,000 g/mol) and Eudragit® L
(MW 125,000 g/mol) were obtained from Rohm GmbH & Co.KG,
Pharma Polymers, Darmstadt, Germany. Poly(lactic acid) (PLA) was
purchased from Futerro, Escanafﬂes, Belgium. Isocratic HPLC grade
methanol and acetonitrile were purchased from VWR International,
East Grinstead, UK. L-132 lung epithelial cells were purchased from
the American Type Culture Collection (ATCC) and EpiSkin™ was
purchased from Skin Ethic Laboratories, Lyon, France. The human
IL-1α ELISA kit and Bradford assay kit were purchased from Pierce,
Rockford, IL, USA. Gantrez® AN-139, a co-polymer of methyl vinyl
ether and maleic anhydride (PMVE/MAH, MW 1,080,000 Da) and
Gantrez® MS-955, a mixed sodium and calcium salt of methyl vinyl
ether and maleic anhydride copolymer (PVM/MA, MW 1,000,000
Da) were gifts from Ashland, Kidderminster, UK. All other chemicals
used were of analytical reagent grade.
2.2. Microneedle array fabrication
Laser-engineered silicone micromould templates were used in
micromoulding of MN arrays and were microfabricated using a
previously-reported approach [15]. The arrays were composed of
361 (19 × 19) needles perpendicular to the base, of conical shape
and 600 μm in height, with base width of 300 μm and interspacing
of 50 μm. The array area was approximately 0.49 cm2. In order
to test the compatibility and suitability of a number of different
polymers as potential matrices in the formation of polymeric MN
arrays with high loadings of incorporated ibuprofen sodium, various
aqueous gel formulations were prepared, as summarised in Table 1.
Approximately 300 mg of the relevant polymer gel/drug preparation
was poured into the silicone moulds and these were centrifuged for
15 min at 550 ×g. Following centrifugation, the MN arrays were
dried in the moulds at room temperature for 48 h. The MN arrays
were then carefully removed from the moulds and assessed visually
for mechanical strength and formulation homogeneity.
2.3. Fabrication of PMVE/MA microneedle arrays incorporating ibuprofen
sodium
After numerous iterations, MN arrays prepared using the free acid
co-polymer poly(methylvinyl ether/maleic acid) (PMVE/MA), pro-
duced by aqueous hydrolysis of the PMVE/MAH supplied as described
previously [11,15,16], were found to have superior properties to other
compositions (Fig. 1B). To prepare such arrays, relevant masses of ibu-
profen sodium and a 30% w/w PMVE/MA gel, the pH of which had
been altered to 7.0 using sodium hydroxide (NaOH) pellets, were
added together so as to generate a formulation of polymer gel:drug in
the ratio 70%:30%. This formulation was then poured into the silicone
micromoulds, centrifuged for 15 min at 550 ×g and again allowed to
dry under ambient conditions for 48 h.
2.4. Rheological characterisation of PMVE/MA gels containing ibuprofen
sodium
In order to consider the processability of gels with such high
drug loadings, continuous ﬂow rheological assessment of the
gels was performed using a TA Instruments AR 1500 Rheometer
(TA Instruments, Elstree, Herts, UK) ﬁtted with a 40 mm diameter
steel parallel plate. Flow rheology was conducted at 25 °C in
continuous ramp mode with the shear rate increased from 0 to 50
1/s. Viscosity was determined by application of the Power law.
2.5. Determination of water content of PMVE/MA microneedles
incorporating ibuprofen sodium
The percentage water content of the ibuprofen sodium-loaded
PMVE/MAMN arrays was determinedwith a Q500 ThermoGravimetric
Analyser (TA Instruments, Elstree, Herts, UK). Samples of 5.0–10.0 mg
were heated from ambient temperature to 600 °C at a heating rate of
10 °C min−1. Nitrogen ﬂow rates of 40 ml min−1 (balance purge gas)
and 60 ml min−1 (sample purge gas) were maintained for all samples.
The data from thermogravimetric analysis experiments was analysed
with TA Instruments Universal Analysis 2000 software, version 4.4A
(TA Instruments, Elstree, Herts, UK).
2.6. Mechanical testing of microneedle arrays
MN arrays were subjected to mechanical tests for compression
and skin insertion. The mechanical properties were evaluated using a
TA-XT2 Texture Analyser (StableMicrosystems, Haslemere, UK) in com-
pression mode, as described previously [15] (Fig. 1C). MN arrays were
visualised before and after application of the compression load using a
Fig. 1. Schematic illustration of the mechanism of drug delivery from dissolving
microneedle arrays with containing ibuprofen sodium (A). Digital image of the optimised
formulation for dissolving microneedles containing ibuprofen sodium (B). Texture
Analyser/light microscopy set-up for investigation of physical properties of microneedles
(C) and Franz cell set-up for in vitro transdermal drug release studies (D). Indication of bi-
ological testing of microneedles in 3D (E) and 2D (F) cell culture models.
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light microscope (GXMGE-5 digital microscope, Laboratory Analysis
Ltd., Devon, UK).
To investigate insertion properties, neonatal porcine skin, previously
determined to be a good model for human skin in terms of hair sparse-
ness and physical properties [17,18] was obtained from stillborn piglets
and immediately (b24.0 h after birth) excised and trimmed to a
thickness of 350 μm using an electric dermatome (Integra Life Sci-
ences™, Padgett Instruments, NJ, USA). Skin was then stored at
−20 °C until required. Before performing penetration studies, the skin
was carefully shaved using a disposable razor and stained with methy-
lene blue aqueous solution (1%w/v). The solution was gently wiped off,
with dry tissue paper and then with saline and alcohol swabs. The skin
Table 1
Summary of the content of the various aqueous blends tested in theproduction of dissolvingMN arrays loadedwith ibuprofen sodium. In all cases, representative images of the formedMN
are provided.
50% w/w PLA:50% w/w ibuprofen-sodium 21% w/w Eudragit®L:30% w/w ibuprofen-sodium
Stamp moulded MN arrays tacky Needles on the MN arrays were shallow and did not
form completely.
18% w/w Eudragit®S:30% w/w ibuprofen-sodium 21% w/w PVA:30% w/w ibuprofen-sodium
There was distinct separation of drug and polymer in
the MN arrays
Insoluble drug/polymer aggregates formed in the
polymer gel and subsequently in the MN arrays.
21% w/w PVA:30% w/w ibuprofen-sodium 14% w/w Gantrez®MS-955, pH 6.0:30% w/w
ibuprofen-sodium
Insoluble drug/polymer aggregates formed in the
polymer gel and subsequently in the MN arrays.
MN arrays were extremely brittle and needles did not
form entirely.
70% w/w alginic acid:30% w/w ibuprofen-sodium 10.5% w/w alginic acid:30% w/w ibuprofen-sodium
The polymer/drug mix was not homogenous and MN
arrays were subsequently brittle.
Needles broke off the MN arrays as they were removed
from moulds.
3% alginic acid:40% w/wibuprofen-sodium 18% w/w PVP, pH 6.0:40% w/w ibuprofen-sodium
MN arrays were extremely brittle when removed
from moulds.
MN arrays were extremely brittle.
18% w/w PVP:1.5% w/w Eudragit®L, pH 7.0:40% w/w
ibuprofen-sodium
15% w/w PVP:6% w/w Eudragit®S pH 7.0:40% w/w
ibuprofen-sodium
Needles did not form and MN arrays were extremely
brittle.
MN arrays were brittle and needles did not form.
18% w/w PVP:0.75% w/w Eudragit®S:40% w/w
ibuprofen-sodium
18% w/w PVP:0.75% w/w Eudragit®L:40% w/w
ibuprofen-sodium
MN arrays were extremely brittle and broke upon
removal from the moulds.
Needles were fragile and broke off when MN arrays were
removed from moulds.
18% w/w PVP:1.5% w/w Eudragit®L:40% w/w
ibuprofen-sodium
15% w/w PVP:6% w/w Eudragit®S:40% w/w
ibuprofen-sodium
Needles were fragile and broke off when MN arrays
were removed from moulds.
Drug was insoluble in the polymer gel.
12% w/w PVA:40% w/w ibuprofen-sodium
Needles were fragile and broke off when MN arrays
were removed from moulds.
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was placed, dermis side down, on a 500 μm-thick sheet of dental wax
(Anutex®, Kemdent Works, Swindon, UK) topped with Paraﬁlm®
(Alpha Laboratories, Hampshire, UK) and this assembly was then
secured on a wooden block for support. Using double-sided adhesive
tape, MN arrays were carefully attached to the moveable cylindrical
probe. The probe was lowered onto the skin at a speed of 0.5 mm s−1
until the required force was exerted. Forces were held for 30 s with
known forces of 0.4 and 0.5 N per needle. Once the target force was
reached, the probe was moved upwards at a speed of 0.5 mm s−1.
After removal of MN arrays, the skin was viewed under the digital
microscope. The surface of the stained skin was then photographed
using the digital camera and the number of microconduits was
determined visually.
2.7. Determination of ibuprofen sodium recovery from MN arrays
In order to determine the percentage recovery of ibuprofen sodium
from dissolving MN arrays, the arrays were dissolved in 100 ml PBS
(pH 7.4) in a volumetric ﬂask and two 10-fold dilutions were subse-
quently carried out in PBS. The drug content of each MN array was
determined by HPLC as described below and the percentage recovery
of ibuprofen sodium was then determined.
2.8. Microneedle in-skin dissolution kinetics
The dissolution rate of the ibuprofen sodium-loaded PMVE/MA MN
arrays was investigated in dermatomed neonatal porcine skin. The
skin samples were carefully shaved using a disposable razor and then
equilibrated in PBS (pH 7.4) for 15 min. A circular specimen of the
skin was then dried and carefully secured to the donor compartment
of a modiﬁed Franz diffusion cell (FDC-400 ﬂat ﬂange, 15 mm oriﬁce
diameter, mounted on an FDCD diffusion drive console providing
synchronous stirring at 600 rpm and thermostated at 37 ± 1 °C,
Crown Glass Co. Inc., Sommerville, NJ, USA) using cynoacrylate glue
(Loctite Ltd, Dublin, Ireland) with the stratum corneum accessible via
the top of the donor compartment. This was then placed on a piece
of dental wax to support the skin and MN arrays were inserted into
the centre of the skin section using a custom-made applicator device
(11.0 N force) [15]. To ensure the MN arrays remained within the
skin, a circular steel weight (diameter 11.0 mm, 5.0 g mass) was placed
on top of the MN arrays. With the arrays in place, donor compartments
were mounted onto the receptor compartments of the Franz cells.
At the indicated time points, the arrays were removed from the skin,
ﬂash frozen in liquid nitrogen, and stored at −20 °C until viewing.
MN arrays were viewed using a Leica MZ6 dissection microscope
(Leica Microsystems (UK) Ltd., Milton Keynes, UK) ﬁtted with a Nikon
Coolpix 950 digital camera (Nikon UK Limited, Surrey, UK).
2.9. In vitro drug delivery studies
Diffusion of ibuprofen sodium released from dissolving PMVE/MA
MN arrays across dermatomed (350 μm) neonatal porcine skin was in-
vestigated in vitro using the modiﬁed Franz diffusion cells, as described
previously [11] (Fig. 1D). The MN array was placed on top of the skin
and again inserted using the custom-made applicator (11 N). A piece
of occlusive dressing (Scotchpak™ 9732, 3 M, Carrickmines, Ireland,
coated with a 1.0 mm layer of DuroTak™ 34-416A, National Starch &
Chemical Company, Bridgewater, NJ, USA), identical to that used in
the in vivo studies described below, was used to secure the MN arrays
in place. The cylindrical 5.0 g stainless steel weight was again placed
on top of the occluded array and the donor compartment of the appara-
tus was clamped onto the receiver compartment. The donor compart-
ment and sampling arm were sealed using Paraﬁlm®. The receiver
compartment contained PBS (pH 7.4) degassed prior to use and
thermostated to 37 ± 1 °C. Syringes (1.0 ml) with 8.0 cm needles
were used to remove 200 μl of the Franz cell contents at appropriate
time points and 200 μl of pre-warmed PBS was subsequently added to
replace this. Samples were centrifuged for 5 min at 14,000 ×g using an
Eppendorf Minispin centrifuge (Eppendorf UK Limited, Stevenage, UK)
and appropriately diluted in PBS prior to HPLC analysis.
In in vitro studies exploring the combinatorial approach of iontopho-
resis and dissolving MN arrays, a silver wire (acting as the anode) was
placed into the receiver medium via the side arm of the Franz cell and
a silver–silver chloride electrode (acting as the cathode) was placed
on top of the dissolving MN array. A commercially available power
supply (Phoresor II, Iomed, Salt Lake City, FL, USA) was used to deliver
a current of 0.5 mA cm−2 over a 6 h period. Sampling and analysis
were performed as described above.
2.10. Biocompatibility studies
Since both polymer and drug are deposited in skin by dissolvingMN,
their inﬂuence on cellular viability and irritancy are of great interest.
Initial studies here were in vitro, with both 2D and 3D cell culture
models employed. Human L-132 lung cells, engaged as an epithelial
cell model in this study, were routinely maintained in Minimum
Essential Medium (MEM, Invitrogen, Paisley, UK) supplemented with
10% foetal bovine serum (FBS). Cells were cultured in tissue culture
plasticware (Thermo Scientiﬁc, Waltham, MA, USA) and housed in a
humidiﬁed incubator at 37 °C, with a CO2 content of 5% (Fig. 1F).
Sodium dodecyl sulphate (SDS) was used as a positive control, as it
has long been recognised as a human skin irritant [20] and has been
demonstrated to induce the production and release of the irritancy
biomarker, interleukin-1α [IL-1α] [21,24]. All test compounds (ibupro-
fen sodium, PMVE/MA, ibuprofen sodium-loaded PMVE/MAMNarrays)
were dissolved in cell culture medium and were ﬁlter-sterilised using a
0.2 μm ﬁlter prior to their addition to the cells. The negative control was
cell culture medium alone. During cell viability and IL-1α expression
analysis experiments, L-132 cells, at a density of 105 cells/well, were
transferred to 24-well tissue culture plates, in a total volume each of
500 μl. The cells were incubated in these conditions overnight, allowing
the cells to achieve conﬂuence. The following day, the 500 μl cell culture
medium was removed and replaced with 300 μl of fresh medium
containing test agent at the appropriate concentration. The cells were
then returned to the incubator for 24 h.
EpiSkin™ 3D skin constructs were treated as recommended by the
manufacturer (Fig. 1E). EpiSkin™ was exposed to the test compounds
for 60 min. This exposure time was decided upon following communi-
cations with the manufacturer — 15 min exposure of EpiSkin™ was
recommended for ‘raw materials’, with longer exposure times of
60 min recommended for ‘ﬁnished products’.
To assess cell viability, the cell monolayers were washed with 500 μl
sterile PBS (pH 7.4) and were then replenished with MEM containing
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
reagent at 1 mg ml−1. The cells were then returned to the incubator
for a ﬁnal 2 h. The MTT assay is a gold-standard assay for determining
cell viability and is based on the ability of viable cells to reduce
the water-soluble MTT to a water-insoluble formazan product [22,23].
The cell supernatants, following 2 h incubation of the cells in the MTT
containing medium, were discarded and 500 μl of dimethyl sulfoxide
(DMSO) was added to each well of the 24 well plate to solubilise
the formazan product. The plates were shaken for 2 min to assist
solubilisation, before 200 μl aliquots were transferred to duplicate
wells of a 96-well microplate for absorbance measurement. The
absorbance was measured at 550 nm, with DMSO acting as a
background control.
To assess the release of IL-1α into the cell culture medium in
response to the various test stimuli, the MEM that was reserved in the
viability test was used in a commercially available human IL-1α speciﬁc
ELISA, following the manufacturer's guidelines. Additionally, cellular
production (cell-associated IL-1α) of the same cytokine in the absence
of cellular secretion was also investigated. The cells were similarly
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challenged and following treatment, were lysed in PBS (pH 7.4) con-
taining 0.5% (v/v) Triton-X-100 on an upright carousel at 4 °C. Cell
lysates were analysed for IL-1α content according to manufacturer's
instructions [24]. The total protein content of the cell lysates was also
assessed in order to normalise data in the case of cell-associated IL-1α
measurement. This was performed using the standard Bradford assay
(Pierce, Rockford, IL, USA) for protein concentration determination.
IL-1α levels were expressed as pg IL-1α/μg total protein and were
then converted to represent the relative IL-1α expression of the
cells as a percentage of that expressed by those cells incubated
under control conditions.
2.11. In vivo tolerance study
Tolerance studies using the PMVE/MA MN arrays were carried
out prior to the commencement of in vivo experiments, in order to
determine whether the formulation or the occlusive dressing to be
used in subsequent experiments caused any irritation to the rats. Four
MN arrays or pieces of occlusive dressings alone were applied using
gentle ﬁnger pressure to the shaved backs of each of 2 rats and secured
in place for 24 hwithmedical tape (Micropore®, 3M, St. Paul, MN,USA).
These were then removed following 24 h and the rats were monitored
for any signs of irritation on their skin and any other adverse effects
for up to 7 days post removal of the MN and/or occlusive dressing.
2.12. In vivo evaluation
All male Sprague dawley rats were acclimatised to laboratory
conditions for a 7 day period. To prevent fur from interfering with
dermal contact of the patch, animals were anesthetised using gas
anaesthesia (2–4% isoﬂurane in oxygen) 24 h before experimentation,
and the hair was removed with an animal hair clipper. Additionally,
depilatory cream (Boots Expert®, The Boots Company PLC, Nottingham,
UK) was used to remove any residual hair. This was followed by a one
day recovery period to facilitate the re-establishment of skin barrier
function [11,22]. The following day, the rats were again anaesthetised
immediately prior to MN array application. Four dissolving MN arrays,
which had each been secured onto an open “frame” of approximately
1.6 cm2 area made from adhesive foam (TG Eakin Ltd, Comber, Co.
Down, UK)were applied opposite each other using ﬁrm ﬁnger pressure
onto a pinched section of skin on the back of the rat, as illustrated in
Fig. 5A. This orientation of application was used as a means to apply
equal pressure to the two opposing arrays. An occlusive dressing was
carefully applied over the MN arrays and these were then secured in
place by gently wrapping the animal in Micropore® tape, avoiding
the legs. The rats were returned to their cages and tail vein bleeds
(no more than 200 μl per sample) were collected into heparinised
tubes at designated time points: 1, 2, 4, 6 and 24 h. The MN arrays
were left in place for 24 h. Plasma was separated from the whole
blood samples and prepared as described below, prior to HPLC analysis.
Approval for animal experiments was obtained from the Committee
of the Biological Research Unit, Queen's University Belfast. The
work was carried out under the Project Licence PPL 2678 and the Per-
sonal Licence PIL 1466. All in vivo experiments were conducted ac-
cording to the policy of the federation of European Laboratory
Animal Science Associations and the European Convention for the
protection of vertebrate animals used for experimental and other
scientiﬁc purposes, with implementation of the principles of the
3R's (replacement, reduction, reﬁnement).
2.13. Extraction of plasma and drug
Control rat blood for assay method development was obtained from
healthy Sprague dawley rats. Blood from culled rats was collected via
heart puncture with a heparinised syringe into ethylenediaminetetra-
acetic acid (EDTA)-coated tubes. Plasma separation was performed by
centrifuging the blood at 500 ×g for 10 min in a refrigerated centrifuge
(4 °C). The plasma was then aliquoted into microtubes and stored
at −80 °C until required. Aliquots (10 μl) of ibuprofen sodium
working standard solutions were added to 190 μl blank plasma.
The sample was vortex mixed for 10 s in a poly(propylene) microtube
and 500 μl acetonitrile (ACN) was then added. The sample was vortex
mixed for 10 min and centrifuged at 14,000 ×g for 10 min at 4 °C. The
ACN extraction procedure was then repeated to ensure optimum
extraction of the drug. The sample mixture was placed in a dispos-
able glass culture tube and the extract was dried under a stream of
nitrogen at 35 °C for 50 min using a Zymark TurboVap® LV Evaporator
Workstation. The residue was then reconstituted in 200 μl PBS (pH 7.4)
and collected into a microtube. This was then vortex mixed for 30 s
and centrifuged at 14,000 ×g for 10 min at room temperature. The
supernatant was transferred into an autosampler vial and 50 μl was
injected onto the HPLC column.
2.14. Pharmaceutical analysis of ibuprofen sodium
Ibuprofen-sodium quantiﬁcation in PBS and rat plasma was per-
formed using reversed phase HPLC (Agilent 1200® Binary Pump,
Agilent 1200®, Standard Autosampler, Agilent 1200® Variable
Wavelength Detector, Agilent Technologies UK Ltd, Stockport, UK)
with UV detection at 220 nm. Gradient separation was achieved
using an Agilent Eclipse XDB-C18 (5 μmpore size, 4.6 × 150 mm) an-
alytical column ﬁtted with a guard cartridge of matching chemistry.
Themobile phase was 60%:40%methanol:10 mMpotassium phosphate
(pH 4.6), with a ﬂow rate of 1 ml min−1 and a run time of 30 min per
sample. The injection volume was 50 μl. The chromatograms obtained
were analysed using Agilent ChemStation® Software B.02.01. Least
squares linear regression analysis and correlation analysis were per-
formed on the triplicate calibration curves produced on each of three
separate days, enabling determination of the equation of the line, its
coefﬁcient of determination and the residual sum of squares (RSS).
To determine the limit of detection (LoD) and limit of quantiﬁcation
(LoQ), an approach based on the standard deviation of the response
and the slope of the representative calibration curve was employed,
as described in the guidelines from the International Conference
on Harmonisation (ICH) [19]. Ibuprofen sodium either dissolved in
PBS (standards), or samples collected from the Franz cell apparatus
(unknowns), was quantiﬁed by injection of the sample, following ﬁlter
sterilisation through 0.2 μm ﬁlters, directly onto the HPLC column.
In the case of plasma samples, the drug was ﬁrst extracted from the
plasma, as described above, and then the resulting sample, which had
been reconstituted in PBS and ﬁltered, was injected onto the column.
The method parameters for detection of ibuprofen sodium in PBS and
plasma were identical.
2.15. Statistical analysis
Where appropriate, data was analysed using the Student's t-test,
one-way ANOVA with post-hoc comparisons, or Mann–Whitney
U-test. In all cases, p b 0.05 denoted signiﬁcance. Statistical Package
for the Social Sciences, SPSS 18.0 version 2.0 (SPSS, Inc., Chicago, IL, USA),
was used for all analyses.
3. Results
3.1. MN array fabrication
In this study, a range of commonly employed ﬁlm-forming FDA-
approved pharma polymers were investigated for their suitability
in the preparation of a novel dissolving MN system loaded with
high doses of ibuprofen-sodium. The MNs prepared have been
summarised in Table 1, with brief accompanying comments relating
to their identiﬁed properties. Some of the polymers tested in
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this study, used in various combinations and in various different
drug loading ratios, were: Eudragit®L, Eudragit®S, poly(lactic acid)
(PLA), poly(vinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP),
Gantrez® MS-955 and alginic acid. For a variety of reasons, outlined
in Table 1, the vast majority of the polymers investigated were not
suitable for use in production of the intended drug-containing
MN arrays. The co-polymer which showed the most promise and
potential was the copolymer, poly(methyl vinyl ether/maleic acid)
(PMVE/MA), prepared by aqueous hydrolysis of the parent anhydride
Gantrez® AN-139.
Drug-loaded MN arrays were then formulated using a range
of PMVE/MA stock concentrations at either pH 2.0 or pH 7.0, in
combination with a range of different ibuprofen sodium loadings,
ranging between 5 and 50% w/w. The formulation that produced
the MN arrays with the most desirable characteristics, in terms
of mechanical properties, as well as the highest achievable drug
loading was fabricated in a ratio of 70% PMVE/MA 30% w/w gel,
pH 7.0:30% ibuprofen sodium. Fig. 1B is a representative digital
photograph of a dissolving MN array in a 19 × 19 format, therefore
totalling 361 individual MN projections per array, each with height
of 600 μm, base width of 300 μm and interspacing of 50 μm on an
array area of approximately 0.49 cm2. These MN arrays were pre-
pared using approximately 300 mg of the gel. Upon drying, approx-
imately 40% of this mass was lost due to evaporation of the water
contained within, resulting in arrays containing approximately
50% w/w active agent.
3.2. Rheological characterisation
The rheological and mechanical properties of the gel formed when
the candidate polymer, PMVE/MA was mixed with ibuprofen sodium
(70% PMVE/MA 30% w/w, pH 7.0:30% ibuprofen sodium) were de-
duced. The viscosity of a polymer solution depends on concentration,
size (i.e. molecular weight) of the dissolved polymer, pH, tempera-
ture, ionic strength and additives at a given shear rate. The viscosity
of 30% w/w PMVE/MA, pH 7.0 decreased signiﬁcantly (p b 0.001)
after the addition of the ibuprofen sodium. This was possibly due to
dampening of electrostatic repulsion between the ionisable free
acid groups caused by the presence of the additional sodium content
of the gels formed (Fig. 2A).
3.3. Mechanical testing of MN arrays
The Texture Analyser was used to determine the mechanical
strength of the ibuprofen sodium-containing PMVE/MA MN arrays.
As applied force was increased, there was a progressive decrease in
MN height but, notably, none of the MN fractured, rather they be-
came somewhat compressed (Fig. 2B). In general, increasing the
forces applied per needle resulted in an increase in the penetration
efﬁciency of the arrays, as shown in Fig. 2D. The percentage of
microconduits successfully created in the skin at insertion forces of
0.40 and 0.50 N/needle were approximately 90% and 100%, respective-
ly. In both cases, microconduits could also be traced on the surface of
the laboratory ﬁlm (Paraﬁlm®) placed underneath the dermatomed
neonatal porcine skin, Fig. 2D (ii) and (iv).
3.4. Water content determination and ibuprofen sodium content
The bound and free water of the ibuprofen sodium-containing
PMVE/MAMN arrays, as determined using thermogravimetric analysis,
were 7.22± 0.64% and 3.50± 0.53%, respectively (means± S.D., n=3).
The percentage recovery of ibuprofen sodium from MN arrays which
were dissolved post-casting in a known volume of PBS (pH 7.4) was
99.6 ± 0.46% (means ± S.D., n = 6) (Fig. 3A).
3.5. In-skin dissolution studies
Dissolution of the needles was evident after as little as 30 s and the
needles had completely disappeared after 5 min. An additional dissolu-
tion study was carried out in which dissolving MN arrays were placed
into ﬂasks containing 20 ml PBS (pH 7.4). The dissolution time for MN
arrays was 4.39 ± 0.88 min. These experiments indicate the rapidity
of MN dissolution using this drug delivery system.
3.6. Pharmaceutical analysis of ibuprofen sodium
HPLC methods for the quantiﬁcation of ibuprofen-sodium, in either
PBS or plasma, were validated according to ICH guidelines. Limits of
quantiﬁcation and detection were determined and are presented in
Table 2(i) and (ii), respectively.
3.7. In vitro drug delivery from ibuprofen sodium-loaded dissolving
PMVE/MA MN arrays
Ibuprofen sodium was detected in the receiver compartment of the
Franz cells by HPLC analysis 15 min following application of MN arrays
and the concentration of drug in the cells increased in a time-dependent
manner until the end of the release experiment (24 h) (Fig. 3B). MN
arrays delivered a total of 33.5 ± 6 mg of ibuprofen sodium in 24 h.
TheMN arrays contained an average total of 37.24± 2.25mg ibuprofen
sodium, meaning that approximately 90% of the contained drug loading
was delivered across the dermatomed neonatal porcine skin in 24 h.
Fig. 2. Viscosity of 30%w/w PMVE/MA, pH 7.0 gel formulation and the 70% PMVE/MA 30%
w/wgel, pH 7.0:30% ibuprofen sodium formulation (optimisedmicroneedle formulation),
(means ± S.D., n = 5) (A). Digital microscope images of dissolving PMVE/MA
microneedles loaded with ibuprofen sodium following the application of different forces
(0.05, 0.4, 0.5 and 1.0 N/needle).Microneedle arrayswere attached to themoveable cylin-
drical probe (length 5.0 cm, cross-sectional area 1.5 cm2) of the Texture Analyser using
double-sided adhesive tape and an axial compression load was then applied. The test sta-
tion pressed the MN arrays against a ﬂat block of aluminium at a rate of 0.5 mm s−1 with
deﬁned forces for 30 s. The pre- and post-test speeds were 1.0 mm s−1 and the trigger
force was set at 0.049 N. These images are representative of the percentage reduction in
the heights of needles on theMN arrays observed following the application of the different
forces (means + S.D., n = 3). The scale bars represent a length of 300 μm (B). Represen-
tative digital micrographs illustrative of the dissolution of ibuprofen sodium-loaded dis-
solving microneedle arrays (prepared from gels comprised of 70% PMVE/MA 30% w/w
gel, pH 7.0:30% ibuprofen sodium) at speciﬁc time points (T0: 0 min; T0.5: 0.5 min; T1: 1
min etc.) over a 30min period following insertion into, and removal from excised neonatal
porcine skin (C). Digital images showing microconduits on methylene-blue stained neo-
natal porcine skin after application of forces of (i) 0.4 & (iii) 0.5 N/needle to ibuprofen
sodium-loaded dissolving PMVE/MA microneedle arrays. The images presented in (ii)
and (iv) are the reciprocal images of the etching visible on the laboratory ﬁlm (Paraﬁlm®)
lying under the microneedle arrays following force application (D).
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3.8. Cathodal iontophoresis
Cathodal iontophoresis coupledwith the utilisation of the dissolving
MN delivery system may result in increased rates of skin permeation.
This was investigated here and Fig. 3C illustrates the permeation
proﬁles of ibuprofen sodium following cathodal iontophoresis (IP),
at a current density and duration of 0.5 mA cm−2 and 6 h, respectively.
The combination of cathodal IPwith this dissolvingMN delivery system
led to an enhancement in ibuprofen sodium permeation across the
dermatomed neonatal porcine skin over a 6 h sampling period, in com-
parison to the dissolvingMN array used in isolation. This difference was
not signiﬁcant, however (p N 0.05) as 26.65 ± 0.43 mg of drug was
delivered in the case of MN arrays used in isolation, as compared to
31.98 ± 0.78 mg of drug delivered when MN arrays and IP were used
in combination. The in vitro permeation of ibuprofen sodium using the
combinatorial approach of dissolving MN arrays and cathodal IP was
then followed for a shorter period of 30min only (Fig. 3D). The quantity
of ibuprofen sodiumwhichwas successfully delivered using the combi-
nation of dissolving MN arrays and cathodal IP was signiﬁcantly higher
(p b 0.05) than that achieved with MN arrays only at 1, 5 and 10 min.
Following these initial sampling time points, there was no signiﬁcant
difference between the quantities of drug delivered at subsequent
time points using the two different delivery strategies. Accordingly,
due to its limited value and impractical nature, IP was discontinued at
this stage.
3.9. Biocompatibility studies
Two concentrations of each of PMVE/MA and ibuprofen sodi-
um were used in all biocompatibility tests, namely 0.116 and
2.5 mg ml−1, while two concentrations of dissolved MN formulation
were also employed; namely 0.232 and 5 mg ml−1. In in vitro delivery
experiments, the concentration of ibuprofen sodium in the receiver
compartment after 15 min was approximately 0.116 mg ml−1 and
that after 6 h was approximately 2.5 mg ml−1. These concentrations
were doubled for the dissolved MN formulation to reﬂect the high
drug and polymer loadings (approximately 90% in total) and the fact
that the mechanism of action of the device involves deposition of
both in the skin. Exposure of L-132 lung ﬁbroblasts, used an epithe-
lial cell model in this study, to low concentrations of ibuprofen sodi-
um (0.116 mg ml−1), PMVE/MA (0.116 mg ml−1) or MN
formulation (0.232 mg ml−1) had no detrimental effects on cell vi-
ability (Fig. 4A). Exposure to the higher concentration of PMVE/
MA (2.5 mg ml−1) also did not lead to a signiﬁcant reduction in
cell viability. Exposure to high concentrations of ibuprofen sodium
(2.5 mg ml−1) and the MN formulation (5 mg ml−1) negatively im-
pacted cell viabilities, as the relative viability of the cells decreased
Fig. 3. Percentage recovery of ibuprofen sodium from dissolving PMVE/MA microneedle
arrays (means± S.D., n = 6) (A). The in vitro cumulative permeation proﬁle of ibuprofen
sodium across dermatomed 350 μm neonatal porcine skin when delivered using in-
dwelling dissolving PMVE/MA microneedle arrays (means ± S.D., n = 6) (B). The inset
chart shows the mass balance following completion of the 24 h delivery experiment as
compared to the theoretical loading of ibuprofen sodium. The in vitro cumulative perme-
ation proﬁle of ibuprofen-sodium across dermatomed 350 μmneonatal porcine skinwhen
combining iontophoresis (0.5 mA cm−2) and in-dwelling dissolving PMVE/MA
microneedle arrays for a period of 6 h (MN + IP), or passive delivery from dissolving
microneedle arrays only (MN) (means± S.D., n = 5) (C). The in vitro cumulative perme-
ation proﬁle of ibuprofen-sodium across dermatomed 350 μmneonatal porcine skinwhen
combining iontophoresis (0.5 mA cm−2) and in-dwelling dissolving PMVE/MA
microneedle arrays for a period of 30 min (MN+ IP), or passive delivery from dissolving
microneedle arrays only (MN) (means ± S.D., n = 5) (D).
Table 2
Calibration curve properties for ibuprofen sodium quantiﬁcation in (i) PBS (pH 7.4) and
(ii) rat plasma, as determined by linear regression and correlation analyses, and limits of
detection and quantiﬁcation for ibuprofen sodium.
Slope y-Intercept R2 LoD (μg/ml) LoQ (μg/ml)
(i) 103.27 10.576 0.9996 0.992 1.25
(ii) 109.83 17.876 0.9991 0.7 2.2
Fig. 4. Effects of 24 h exposure, on the viability of human L-132 ﬁbroblasts, to the in-
dicated treatments: Cells incubated in cell culturemedium only (Control); ibuprofen-
sodium only (Ibu-sod); PMVE/MA only (PMVE/MA); MN array formulation (formula-
tion) or SDS positive control (SDS). Cell viability following exposure was expressed
relative to the viability of cells in the control group (means ± S.D., n = 3) (***p =
0.0001) (A). IL-1α content of L-132 cell lysates following 24 h exposure to indicated
treatments: Cells incubated in cell culture medium only (control); ibuprofen-sodium
only (Ibu-sod); PMVE/MA only (PMVE/MA); MN array formulation (formulation) or
SDS positive control (SDS) (means ± S.D., n = 3) (B). The viability of human
keratinocytes in 3D culture (EpiSkin™) (n = 4) following treatment for 60 min,
followed by 42 h recovery with the indicated treatments: Cells incubated in cell cul-
ture medium only (control); ibuprofen-sodium only (Ibu-sod); PMVE/MA only
(PMVE/MA); MN array formulation (formulation) or SDS positive control (SDS).
(means ± S.D., n = 4) (***p= 0.0001) (C). IL-1α content of human keratinocytes in 3D
culture (EpiSkin™) following treatment for 60min, followed by 42h recoverywith the in-
dicated treatments: Cells incubated in cell culture mediumwith a relevant volume of PBS
(control); ibuprofen-sodium only (Ibu-sod); PMVE/MA only (PMVE/MA); MN array for-
mulation (formulation) or SDS positive control (SDS), (means ± S.D., n = 4) (D). The vi-
ability of human keratinocytes in 3D culture (EpiSkin™) following treatment for 60 min,
followed by 42 h recovery with the indicated treatments: MN array formulation (formu-
lation), SDS positive control (SDS) or cells incubated in cell culture medium with a rele-
vant volume of PBS pH 7.4 (negative control), (means ± S.D., n = 4) (*p = 0.0153)
(E). IL-1α content of human keratinocytes in 3D culture (EpiSkin™) following treat-
ment for 60 min, followed by 42 h recoverywith the indicated treatments: Cells incubat-
ed in cell culture mediumwith a relevant volume of PBS (control); MN array formulation
(formulation); SDS positive control (SDS) (means ± S.D., n = 4) (***p= 0.0004) (F).
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to 1.8 ± 0.4% and 1.8 ± 0.2%, respectively (Fig. 4A). These decreases
were deemed to be signiﬁcant (p b 0.0001). A positive control of
0.1% w/v SDS unsurprisingly also led to a signiﬁcant (p b 0.0001) re-
duction in cell viability.
Treatment of L-132 ﬁbroblasts for 24 h with a 0.01% w/v solution
of SDS in MEM resulted in a four-fold increase in the amount of cell-
associated IL-1α (Fig. 4B). Exposure of the cells to 0.116 mg ml−1
ibuprofen sodium or PMVE/MA led to marginal, but not signiﬁcant,
increases in IL-1α expression. Increasing the concentration of the MN
formulation to 0.232 mg ml−1 led to an increase in the expression
of the inﬂammatory marker, but this was not signiﬁcant (p N 0.05).
Treatment with 2.5 mg ml−1 ibuprofen sodium and 5 mg ml−1 MN
formulation had resulted in almost total loss of L-132 viability
(Fig. 4A). Accordingly, these solutions led to undetectable cell-
associated IL-1α levels in the cell lysates (Fig. 4B). No IL-1α was de-
tectable in the culture medium itself following treatment, indicating
that the IL-1α was not secreted by the cells. The data indicates that
the drug and co-polymer, used in isolation or in combination at the
indicated concentrations, were not irritant to the cells. Treatment
of EpiSkin, reconstructed human epidermis, with 5% w/v SDS (the
recommended positive control) for 60 min followed by a 42 h recov-
ery period, resulted in an 80% loss of tissue viability (p b 0.0001)
(Fig. 4C). Similar treatments with ibuprofen sodium, PMVE/MA
(both 0.116 mg ml−1) or MN formulation (0.232 mg ml−1) had no
deleterious effects on tissue viability (Fig. 4C). Analysis of the IL-1α
content of the medium that contained the tissue revealed that treat-
ment with 5% w/v SDS caused a 2000% increase in cytokine produc-
tion relative to the negative control (Fig. 4D). The other treatments
did not affect expression of the cytokine. All exposures were carried
out for 60 min, followed by a 42 h recovery period, according
to the manufacturers' recommendations. Tissues were then ex-
posed to the higher concentration of the MN formulation, namely
5 mg ml−1, for 60 min followed by a 42 h recovery period. This
treatment of the tissues did not have any deleterious effects on
their viability, while treatment with 5% w/v SDS caused a signiﬁ-
cant decrease in cell viability (p = 0.0153) (Fig. 4E). In the recipro-
cal IL-1α expression experiment, the IL-1α content of the medium
was unaffected by treatment with 5 mg ml−1 of the MN formula-
tion. In stark contrast, however, there was a marked increase in
IL-1α expression (11,411 ± 316% relative to the negative control,
p = 0.0004) by those cells treated with the positive control of 5%
w/v SDS (Fig. 4F). The results of the work carried out using both
2D and 3D cultures outlined here was further underpinned by the
results of the tolerance studies carried out in rats prior to the
commencement of in vivo delivery of ibuprofen sodium, whereby
the application of the dissolvingMN arrays held in place using occlusive
dressings for 24 h caused no irritation to the animals. The results of
these two tolerance studies indicated that in vivo experiments could,
therefore, commence.
3.10. In vivo drug delivery and quantiﬁcation
The most appropriate site for the application of the dissolving MN
arrays was determined to be the back, adjacent to the spinal region,
an area less likely to be easily scratched/groomed by the animal.
In addition, this area was chosen so as to ensure that ﬂexing of the
abdominal cavity due to normal breathing and movement could
not potentially cause MN arrays to detach from the skin during the
course of experiments. The application and positioning of the MN
arrays on the backs of the animals is exempliﬁed in Fig. 5A.
It was quickly deduced that MN arrays applied without the adhesive
foam frame had a tendency to become expelled out of the skin upon
release of the application pressure and loosening of the pinched skin.
Therefore, in all in vivo experimentation, these adhesive frames were
employed to secure the arrays in place over the course of the exper-
iment. Following application of the dissolving MN arrays, a
transdermal occlusive dressing was applied, covering and surround-
ing the arrays so as to prevent the animals from removing them dur-
ing routine grooming. Four dissolving MN arrays were applied to the
backs of each of four rats in any given experiment. The average
ibuprofen sodium content in each dissolving MN array was approxi-
mately 76.4 mg. Therefore, as each rat had four dissolving MN arrays
applied, each had an average total of 305.6 mg ibuprofen sodium
applied in the experiment. As is clearly shown in Fig. 5B, the use of
dissolving MN arrays to transdermally administer ibuprofen sodium
resulted in a progressive increase in the plasma concentrations
of the drug within the initial 4 h sampling period, with a maximal
concentration of approximately 339 μg ml−1 achieved within that
timeframe. Furthermore, the use of these dissolving MN arrays
enabled sustained transdermal delivery of ibuprofen sodium over the
24 h investigation period, resulting in a ﬁnal plasma concentration of
approximately 263 μg ml−1.
4. Discussion
The data presented here represents the ﬁrst time a high dose low
molecular weight drug molecule has been delivered using dissolving
microneedles to yield therapeutically-relevant plasma levels. The trans-
dermal route has already been extensively investigated as a potential
means of non-invasive administration of a range of non-steroidal anti-
inﬂammatory drugs (NSAIDs), all of which have relatively high daily
doses. Themajor challenge associated with transdermal NSAID delivery
to date has been poor permeation across the stratum corneum. Dissolv-
ing MN arrays, capable of breaching the skin's outermost layer to
enhance drug delivery, was the focus of the present study. A wide
range of different polymeric formulations were cast into MN moulds
and provisionally assessed for mechanical soundness and polymer/
drug homogeneity. The copolymer which showed the most potential
was PMVE/MA. Blends of ibuprofen sodium/PMVE/MA were prepared
and used to fabricate MN arrays. In contrast to all other formulations
investigated here, the mechanical properties and homogeneity of the
resultant arrays prepared from gels comprising 70% w/w of a 30% w/w
PMVE/MA gel neutralised to pH 7.0 and 30% w/w ibuprofen-sodium
were satisfactory. This formulation was, thus, chosen for subsequent
study. These MN arrays successfully penetrated excised neonatal
porcine skin and had a sufﬁciently high drug content to yield suitable
in vitro and in vivo delivery. Increasing the drug content above 30%
Fig. 5. Schematic representation of application and retention strategies for rat experiments
designed to evaluate in vivo performance of dissolving PMVE/MAmicroneedle arrays (A).
The in vivo plasma proﬁles of ibuprofen sodium (means± S.D., n=4) following transder-
mal delivery using dissolving PMVE/MA microneedle arrays (B). Images of a 10 cm2 ibu-
profen sodium-loaded PMVE/MA dissolving microneedle patch and two closer images of
the same array where the individual needles on the array are clearly visible (C–E).
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w/w produced arrays with a more powder-like consistency and the
MN arrays were incapable of penetrating the skin. Formulations in-
corporating lower drug content were sufﬁciently rigid to penetrate
the skin, but lacked the high NSAID content essential to achieving
the drug delivery target. The dissolving MN arrays prepared in this
study were capable of penetrating the SC of the skin at relatively
low forces. Following insertion into the skin, it is of fundamental im-
portance that the behaviour of the dissolving MN systems is
characterised and understood. Previously reported studies have
shown that the complete dissolution of soluble MN arrays can
range from minutes to hours, depending upon the composition and
water solubility of the polymeric system employed [4,25–27]. The
delivery of ibuprofen sodium to the skin is based upon the dissolu-
tion of the polymeric MN arrays following exposure to the interstitial
ﬂuid. The dissolution of the individual needles on an array upon in-
sertion into neonatal porcine skin in this study took less than
5 min. Although topical ibuprofen preparations are marketed, evi-
dence has shown that these gels are unsuitable for systemic delivery
of the anti-inﬂammatory [28]. One report suggested that rival
ibuprofen-containing topical products varied ﬁve-fold in terms of
ibuprofen delivery capabilities [29]. The high drug content of the
MN formulation investigated in the present study represents a
clear advantage of this polymeric MN delivery system over the typi-
cally low drug content of topical applications (5–10% w/w). Previous
studies have demonstrated the synergistic effect of MN pre-
treatment of skin in conjunction with topical application of NSAIDs
in enhancing transdermal delivery of other drugs [30], but the cur-
rent study is the ﬁrst to achieve the delivery of therapeutically-
relevant concentrations of ibuprofen to plasma. The in vivo rat stud-
ies have yielded results that could ultimately prove important in
progressing transdermal drug delivery. Delivery of ibuprofen sodi-
um from dissolving MN arrays yielded extremely high and
sustained blood plasma concentrations. The therapeutic blood
levels of ibuprofen in humans range between 10 and 15 μg/ml
[31]. Based on this knowledge and our in vivo results, we can cau-
tiously approximate the patch size that might be necessary for use
in human volunteers, appreciating the known differences in rat and
human skin. An average human male weighs approximately 60 kg
[32], which is 180 times greater than the weight of a 340 g rat
(the average weight of rats used in these experiments). The blood
plasma ibuprofen-sodium concentration achieved in the rats
(263 μg ml−1 at the 24 h time point) were approximately 20
times greater than the human therapeutic plasma level and this
was achieved with MN arrays of total approximate area of approx-
imately 2 cm2 (4 × 0.49 cm2). By this rationale, a MN patch design
of no greater than 10 cm2 could potentially deliver therapeutically
relevant concentrations of ibuprofen sodium in humans. Typical
commercialised transdermal patches can be as large as 30 or
40 cm2 (Novartis make Nicotinell® nicotine patches of 30 cm2
[33]; Janssen make Duragesic® CII (fentanyl) patches of 32 and
42 cm2 [34]). Accordingly, it is reasonable to suggest that, following fur-
ther evaluation, ﬁrst in pigs and then human volunteers, an optimised
MN product could ultimately be developed based on the technology
presented here. Indeed, Fig. 5(C–E) shows a 10 cm2 patch made from
our ibuprofen sodium-loaded PMVE formulation. Although treatment
of L-132 cell monolayers with 2.5 mg ml−1 ibuprofen-sodium led to a
decrease in cell viability, it is extremely unlikely that the viable skin
cells would be exposed to such high concentrations of ibuprofen sodi-
um in vivo following MN application, as the fast dissolution kinetics of
theMN arrays, coupled with the ability of the rich dermal microcircula-
tion to rapidly absorb drug substances from the skin [14,22], would ex-
pedite the removal of the active from the local area. This observation is
also of interpretational relevance in the case of L-132 cells treated with
0.232 mg ml−1 MN formulation, which resulted in increased release of
the irritancy biomarker, while absolutely no skin irritation was ob-
served in rats. Treatment of human keratinocytes in 3D culture
(EpiSkin™) with the dissolving MN formulation (up to 5 mg ml−1)
caused no signiﬁcant reduction in the viability of these cells and no
skin irritancy was caused by use of the MN system in the in vivo
model, thus corroborating these points. It is notable that EpiSkin™
was endorsed by the European Centre for the Validation of Alterna-
tive Methods (ECVAM)'s Scientiﬁc Advisory Committee (ESAC) as
‘a reliable and relevant stand-alone test for predicting rabbit skin irrita-
tion’, and is seen as a valid replacement for animal studies of skin
irritancy. EpiSkin™ was the only in vitro model so endorsed. The
EpiSkin™model is suggested as a suitable candidate for in vitro screen-
ing for skin irritation in ISO 10993-10 (Biological evaluation of medical
devices — Part 10: Tests for irritation and skin sensitization). A loss of
50% viability following treatment and recovery is deemed
to constitute irritancy according to the Organisation for Economic
Co-operation and Development (OECD) Test Guideline 439 (In Vitro
Skin Irritation: Reconstructed Human Epidermis Test Method). To this
effect, 5% w/v SDS treatment of EpiSkin cultures resulted in a 62%
drop in cell viability, identifying it as an irritant. The MN formulation
reported here (5 mg ml−1), therefore, lies comfortably within the
non-irritant range, with a loss of only 8.4% cell viability following treat-
ment. In previous work carried out by our Group, the large-molecule
payload of the dissolving MN arrays which was successfully delivered
in vitro was conﬁned to that amount of the active (insulin) contained
within the individual needles of the arrays themselves [11]. In the
current study however, this was not the case. The delivery of 1530 μg
ibuprofen sodium, the theoretical mass of ibuprofen sodium contained
within the dry MNs alone, was vastly exceeded over the course of the
experimental period. In the in vitro studies, approximately 33 mg of
the drug initially loaded into the arrays was delivered. This equates to
approximately 90% of the total loaded drug being successfully delivered
over the 24 h experimental period and demonstrates the signiﬁcant
potential of dissolving MN arrays in facilitated transdermal delivery of
high dose low molecular weight drugs.
5. Conclusion
The work presented here illustrates the potential of appropriately-
formulated dissolving microneedles to deliver a low molecular weight,
high dose drug in therapeutically-relevant doses. This technology
could potentially be harnessed to deliver large quantities of such non-
potent therapeutic agents across the skin's barrier layerwithout causing
irritation. In this way, a common limitation of transdermal delivery,
namely low delivery capacity for non-potent drugs, could possibly be
overcome. This work, therefore, represents a signiﬁcant progression in
the utilisation of microneedle technologies for successful transdermal
delivery of a much wider range of drugs. We are currently progressing
towards clinical evaluations with a range of candidate molecules and
are taking regulatory advice, given that at least 5 mg of polymer is
deposited in each square centimetre of skin with this system.
Investigation of accumulation/distribution and elimination of polymer
from such a dissolving microneedle product designed for regular use is
likely to be essential before regulatory approval.
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